**ROMOSOZUMAB (EVENITY)**

**Black Box Warning**

**Potential risk of myocardial infarction, stroke and cardiovascular death:** Romosozumab may increase the risk of myocardial infarction, stroke, and cardiovascular death. Romosozumab should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors. If a patient experiences a myocardial infarction or stroke during therapy, romosozumab should be discontinued.

**Monitoring**